Skip to main content

Advertisement

Table 5 JS001 clinical response was evaluated per RECIST v1.1 by investigators every 8 weeks

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Histology 1 mg/kg (n = 15) 3 mg/kg (n = 15) 10 mg/kg (n = 6) Total (n = 36) ORR, DCR
Melanoma (n = 22) 1PR, 4SD 1CR, 2PR, 2SD 0PR 1CR, 3PR, 6SD 18.2%, 45.5%
UC (n = 8) 1PR, 2SD (1uPR) 1SD 1PR 2PR, 3SD 25.0%, 67.5%
RCC (n = 6) 1SD 1PR 1PR 2PR, 1SD 33.3%, 50.0%
Total 2PR, 7SD 1CR, 3PR, 3SD 2PR 1CR, 7PR, 10SD 22.2%, 50.0%
ORR, DCR 13.3%, 60.0% 26.7%, 46.7% 33.3%, 33.3% 22.2%, 50.0%  
  1. As of July 31, 2018, among 36 enrolled subjects, 1 confirmed complete response (CR) (acral melanoma), 7 confirmed partial response (PR) (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 confirmed stable disease (SD) (including 1 unconfirmed PR of UC) were observed, for an objective response rate (ORR) of 22.2% (95% CI, 10.1 to 39.2) and a disease control rate (DCR) of 50.0% (95% CI, 32.9 to 67.1)